Processa Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) (Parenthetical) - USD ($)	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Interim Period, Costs Not Allocable [Line Items]
Personnel costs include employee stock-based compensation expense	$ 95,963	$ 227,711
Research and Development Personnel Costs [Member]
Interim Period, Costs Not Allocable [Line Items]
Personnel costs include employee stock-based compensation expense	17,144	46,720
General and Administrative Personnel Costs [Member]
Interim Period, Costs Not Allocable [Line Items]
Personnel costs include employee stock-based compensation expense	$ 52,387	$ 122,655